Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled, Two-arm (1:1 Ratio) Phase IIa Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With de Novo Minimal Change Disease

NCT07710157 is registered in ClinicalTrials.gov with Medical University Innsbruck as lead sponsor.

NCT NCT07710157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07710157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled, Two-arm (1:1 Ratio) Phase IIa Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With de Novo Minimal Change Disease
Lead sponsor
Medical University Innsbruck
Phase
Phase 2
Overall status
Recruiting
Start date
July 13, 2026
Completion date
June 30, 2029
Enrollment
48 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

minimal change disease (mcd)